Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-012880
Filing Date
2025-09-09
Accepted
2025-09-09 15:28:50
Documents
52
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 543993
2 EX-31.1 ex31-1.htm EX-31.1 17379
3 EX-31.2 ex31-2.htm EX-31.2 14009
4 EX-32.1 ex32-1.htm EX-32.1 7607
5 EX-32.2 ex32-2.htm EX-32.2 6734
  Complete submission text file 0001493152-25-012880.txt   2968471

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE curx-20250630.xsd EX-101.SCH 20825
7 XBRL CALCULATION FILE curx-20250630_cal.xml EX-101.CAL 34567
8 XBRL DEFINITION FILE curx-20250630_def.xml EX-101.DEF 58842
9 XBRL LABEL FILE curx-20250630_lab.xml EX-101.LAB 222530
10 XBRL PRESENTATION FILE curx-20250630_pre.xml EX-101.PRE 175906
55 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 370072
Mailing Address 2 JERICHO PLAZA, SUITE101B JERICHO NY 11753
Business Address 2 JERICHO PLAZA, SUITE101B JERICHO NY 11753 718-673-6078
Curanex Pharmaceuticals Inc (Filer) CIK: 0002025942 (see all company filings)

EIN.: 830741390 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42815 | Film No.: 251302999
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)